Humana Inc HUM

Thesis

Humana is a pure-play Medicare Advantage MCO: 83% of premiums come from federal contracts and ~5.2M individual MA members (1.0M in Florida alone) sit at the core. The business is simple in shape: CMS pays a risk-adjusted PMPM, Humana underwrites medical cost, and CenterWell vertically integrates primary care, pharmacy, and home health to bend the medical loss ratio. The compounding case rests on three pillars (1) a 30+ year track record in Medicare with a 32.6% 10-year average ROIC, (2) demographic tailwind as the 65+ population grows ~3% annually for the next decade, and (3) a re-rating once Star Ratings, utilization, and v28 risk-coding pressure normalize. The scorecard reads composite 73, profitability 21, balance sheet 18, capital allocation 20, valuation 14, with FCF conversion of 141% and net debt/EBITDA of -1.92x (i.e., net cash on a covenant basis once you back out regulated cash). Owner earnings TTM of $0.12B is plainly trough; it embeds a Florida MLR shock and Star Ratings reset that the company has guided to recover by 2027. DCF-based IV ($12-25, base $15.76) implies a price/IV of 14.8x, which is absurd for a 32% ROIC business and reflects the use of trough cash flow. On a Book x ROE frame, $18.6B equity at a normalized 15% ROE ~ $2.8B owner earnings, capitalized at 12-14x = $34-39B market cap = $283-325/share. Buy with margin of safety at $200, trim above $310. The math: pay book at trough, harvest the ROE recovery.

Moat

Humana's moat is best framed as scale-driven cost advantage layered with regulatory intangibles, not a Buffett-style consumer brand. Five-lens stress test

1. Cost advantage (NARROW-WIDE). At 5.2M individual MA members plus 4.7M specialty and 1M Florida concentration, Humana is the #2 MA carrier behind UnitedHealth. In Medicare Advantage the unit economics are dominated by (a) bid efficiency, (b) provider contracting leverage, and (c) Star Ratings rebates. Buffett's GEICO playbook is the right analogue: 'GEICO's sustainable cost advantage is what attracted me to the company way back in 1951' [1][6]. Like GEICO, Humana monetizes scale by reinvesting it in lower premiums and richer benefits, which feeds membership growth, which feeds scale. Unlike GEICO, the cost advantage is not absolute -- UNH and Elevance also have national scale, and regional Blues plans can be lower-cost in their home states. The 32.6% 10-year ROIC is consistent with a real cost moat; the 2024-25 margin collapse is consistent with that moat being narrower than bulls assumed when v28 risk coding and Star Ratings hit.

2. Switching costs (NARROW). Medicare beneficiaries enroll annually during AEP (Oct 15-Dec 7) and can switch carriers cheaply. The friction is not contractual; it is behavioral -- seniors are sticky once enrolled because of provider relationships, formulary familiarity, and supplemental benefits (dental, OTC cards, fitness). Annual member retention historically runs ~85-90%, but this falls fast when Star Ratings drop and benefit designs are cut, as 2025 shows. Verdict: real but fragile.

3. Network effects (NONE). MA does not exhibit two-sided network effects in the platform sense. Provider networks are contracted, not emergent.

4. Intangibles -- Star Ratings + regulatory franchise (NARROW, fading). The 4-Star+ rating is worth ~5% bonus payment from CMS and is the single largest non-cost margin driver in MA. Humana's Star Ratings cliff in late 2024 (downgrade of its largest H5216 contract) cost an estimated $1-3B in 2026 revenue. Stars are scoring-formula sensitive and politically administered; CMS keeps tightening cut points. This is an intangible that can be re-earned, but it is not a permanent moat. Comparable to Buffett's warning that 'back-tested models' on regulatory regimes are dangerous when 'universe past and universe current had very different characteristics' [Munger excerpt 1].

5. Pricing power (NONE). MA premium is set by CMS via the bid process. Humana cannot raise price; it can only manage MLR and capture risk-adjustment. This is the fundamental difference from a Buffett insurance business where 'the willingness to walk away if the appropriate premium can't be obtained' [5] is the discipline. In MA, walking away means surrendering members in a county; you can prune unprofitable counties (Humana exited 13 states/200+ counties for 2026) but the structural revenue ceiling is set by CMS.

Competitor stress test ($10B + 5 years): A new entrant with $10B and five years could not replicate Humana's MA platform. CMS contracting requires multi-year operational track record; provider contracts compound over decades; Star Ratings require multi-year scoring history. UnitedHealth's Optum is the only true peer, and it took 15 years and ~$50B in M&A to build. So the operational moat is real -- but the political/regulatory roof is shared with all MA peers and can compress for everyone simultaneously (as 2024-25 demonstrates).

Erosion risk: HIGH on Star Ratings cliff (already happening), MEDIUM on MA payment policy (v28 phase-in 2024-26), LOW on CenterWell vertical integration (this is genuinely accretive to MLR control, similar to GEICO investing in tech 'to improve efficiency... while preserving its position as the industry's low-cost provider' [2]).

Moat verdict: NARROW.

Management & Capital Allocation

Capital allocation under CEO Jim Rechtin (took over July 2024 after Bruce Broussard's retirement) is a transitional story. The 5-choice framework

1. Reinvest in the business. Humana has been investing heavily in CenterWell (primary care clinics for seniors, home health via Kindred at Home, pharmacy). CenterWell primary care now covers ~340 senior-focused clinics. This is a sound strategic bet: vertical integration mirrors UnitedHealth/Optum's playbook and is the single best lever to bend MLR. Returns on these investments have been muted -- CenterWell margins are still building. Reinvest grade: B.

2. Acquisitions. Humana's track record is mixed. The 2017-18 attempted Aetna merger was blocked. The 2018 Kindred at Home acquisition (with private equity partners) was eventually fully bought in 2021 for ~$8.1B; it has underperformed expectations and Humana has since divested the personal care assets. Cigna merger talks in late 2023 were abandoned -- a notable discipline call as Humana walked away rather than overpay. M&A grade: C+.

3. Debt. Long-term debt sits at $12.3B against $18.6B equity. Net debt/EBITDA of -1.92x per the scorecard reflects that Humana carries ~$20B of regulated investments on the balance sheet against the debt. Interest coverage is not meaningfully reported (scorecard null) but is comfortably above 10x in normal periods. Conservative. Debt grade: A-.

4. Buybacks. Share count change over 10 years is -2.4% -- effectively flat. Humana has historically been an opportunistic buyer, not a programmatic one, and importantly suspended buybacks during the 2024 stress to preserve capital for the regulated subs. Average P/IV when buying historically has been reasonable but not exceptional; the company did not aggressively buy back when the stock collapsed from $570 to $230 in 2024-25, which is a missed opportunity by Buffett's standard ('be greedy when others are fearful'). Buyback grade: C.

5. Dividends. Humana pays a modest dividend (~$0.885/qtr, ~1.5% yield). It has been raised most years but is small relative to FCF. This is appropriate for a regulated business that needs to retain capital flexibility for CMS bid cycles. Dividend grade: B.

Communication quality. Broussard's late tenure was marked by guidance whipsaws -- the January 2024 utilization warning that took the stock down 25% in a day, followed by the Star Ratings disclosure later that year, were poorly communicated. Rechtin has been more measured: he reset 2025 guidance early, took the Star Ratings hit transparently, and has been explicit about the 2026-27 recovery path. Improving. Grade: B-.

Overall capital allocator grade: B-. The franchise is well-positioned, the balance sheet is conservative, and the strategic vertical integration thesis is correct. But the buyback miss at the bottom is real -- a Singleton or Buffett would have repurchased aggressively at $230 with $4-5B annual normalized FCF. Rechtin's tenure is too new to grade definitively; the next 18 months on bid discipline (walking away from unprofitable counties, which Humana did meaningfully for 2026) will be the real test. Buffett's insurance commandment #4 -- 'be willing to walk away if the appropriate premium can't be obtained' [1][5] -- applies directly to MA county-level bids, and Humana's 2026 county exits suggest discipline is improving.

Capital allocator: B-

Industry Structure

Porter's Five Forces on the U.S. Medicare Advantage industry

1. Threat of new entrants: LOW. CMS contracting requires multi-year operational history, state-level licensure, provider network depth, and Star Ratings track record. New national entrants (Bright Health, Clover, Oscar) have all struggled or pulled back. Capital is necessary but not sufficient; regulatory capital + operational scoring history is the real barrier. Score: favorable.

2. Bargaining power of buyers: MIXED-TO-HIGH. The buyer is bifurcated. CMS is the ultimate buyer (paying ~$1,200 PMPM on average) and has near-monopsony power over rate-setting via the bid process and risk adjustment formula. CMS has been progressively tightening v28 risk coding (phased 2024-26), which compresses revenue by an estimated 200-300 bps. The individual senior member has low individual power but high aggregate AEP-driven mobility. The combined effect is high buyer power. Score: unfavorable.

3. Bargaining power of suppliers: MEDIUM-HIGH. Hospitals and health systems have consolidated dramatically; in many MSAs there are 1-3 dominant systems that MA plans must contract with or lose members. Pharmaceutical manufacturers exercise pricing power on specialty drugs, and Part D reform under the Inflation Reduction Act is reshaping economics from 2025. Labor costs in clinics and home health are sticky. Provider supplier power has been rising. Score: unfavorable, worsening.

4. Threat of substitutes: LOW-MEDIUM. The substitute for MA is Medicare FFS + Medigap. MA has captured 51%+ of eligible seniors in 2024 and is forecast to hit 60%+ by 2030 because of richer benefits at zero or low premium. The substitute is structurally inferior on benefit design, but if MA payment is cut materially, the gap closes and seniors could revert. Score: favorable but with policy tail risk.

5. Industry rivalry: HIGH AND INTENSIFYING. UnitedHealth (28% MA share), Humana (18%), CVS/Aetna (14%), Elevance (7%), and regional Blues compete on benefit design, network adequacy, and Star Ratings. The 2024-25 cycle has been a margin reset across the industry -- UNH, HUM, ELV, CVS all guided down. Rivalry on benefit richness was excessive in 2022-23 (rich OTC cards, dental, fitness) and is now being walked back. Industry margins are compressing toward a new equilibrium ~3-4% pretax, down from 5-6%. Score: unfavorable, but with consolidation potential.

Value pool location and trajectory. The MA value pool was ~$45B EBIT in 2023, fell to ~$30B in 2025, and is consensus to recover to $50B+ by 2028 as Star Ratings normalize, v28 fully phases in (eliminating uncertainty), and bid discipline returns. The value pool sits with the largest scaled players who can absorb fixed costs over more lives, and with vertically integrated players (UNH/Optum, HUM/CenterWell) who can capture the medical-cost dollar internally. The shift toward value-based care is a 10-year tailwind for HUM specifically.

Counter-evidence to a 'good industry' verdict: the regulatory monopsony risk is real and rising. CMS rate notices, RADV audits, and IRA-driven Part D economics are all moving against MA carriers. Buffett's 1992 warning on health-care liabilities -- 'lengthening life expectancies and soaring health costs would guarantee an insurer a financial battering' [Munger excerpt 3] -- applies directly to the MA payment structure if CMS cuts rates faster than medical inflation.

Industry Verdict: Average. Strong demographic tailwind and barriers to entry, offset by monopsony buyer power and intensifying rivalry. Not 'Excellent' (margin trajectory is compressing) but not 'Poor' (still a profitable, growing market with room for the top 2 to compound).

Inversion (Bear Case)

Bear case (no hedging)

1. The single event that kills this. CMS issues a 2027 rate notice that meaningfully cuts MA benchmarks (say -3% net effective) AND keeps v28 fully phased in AND tightens Star Ratings cut points further. This combination is not hypothetical -- the Biden-era CMS already did exactly this in smaller increments in 2024 and 2025. Under a Vance/Trump-era CMS the political math is unclear; MA is popular with seniors but expensive to taxpayers, and the IRA reconciliation math has put MA in the crosshairs. A single bad rate notice in April 2026 or April 2027 would compress 2027-28 EBIT by $2-3B and re-rate the multiple from 14x to 9x. Stock to $130-150.

2. Why the moat is narrower than bulls think. Bulls quote the 32.6% 10-year ROIC and the GEICO-like cost advantage. Both are illusions. The 32% ROIC reflects a regulated arbitrage between CMS payments (set at 104% of FFS by formula) and HUM's medical cost curve. It is not a competitive moat; it is a policy gift. Five carriers earn similar returns. When the policy gift compresses (v28, Stars, IRA Part D), all five compress simultaneously -- which is what we are watching. The 'cost advantage' versus a regional Blues plan in Texas is essentially zero; HUM does not have GEICO's 5-7 point structural cost edge in any specific market. Buffett's [1] description of GEICO's 'cost advantage... an enduring one... that competitors are unable to cross' simply does not describe HUM. CenterWell vertical integration is real but takes 5-10 years to bend the MLR by 100 bps -- meanwhile CMS is taking 200-300 bps in coding cuts in 24 months.

3. Why management is worse than it appears. Broussard's tenure ended with serial guidance disasters: the January 2024 utilization warning, the Star Ratings cliff, the abandoned Cigna merger, and the Kindred at Home write-down. Rechtin is unproven. The board missed the buyback opportunity at $230-280 in late 2024 and 2025 -- the very moment when Buffett would have been buying. The board is also not reining in long-term debt, which has crept from $9B to $14B over five years. Most damning: HUM ran $4.7B of net income in 2023 and is on track for under $1.5B in 2025 -- a 70% earnings collapse on a 'durable franchise.' If this is what management does in a normal cyclical reset, what happens in a real downturn?

4. What bulls are extrapolating that won't hold. Bulls extrapolate (a) the 2010-2022 MA penetration curve continuing to 70%+, (b) Star Ratings recovery to 4-Star within 2 years, (c) CenterWell margin contribution doubling, and (d) ROIC reverting to 25%+. Each is questionable. (a) MA penetration has political ceiling around 55-60% as IRA Part D economics make MA less attractive for low-income seniors. (b) Star Ratings recovery historically takes 3-4 years not 2 once a major contract is downgraded. (c) CenterWell EBIT margin is 4-6%, not the 15-20% bulls model. (d) ROIC has averaged 32% in a uniquely favorable rate environment; 18% is the right normalized number, not 25%.

5. Valuation trap (multiple compression / regime change). HUM trades at 16.5x TTM earnings and 8.5x EV/FCF. Both look cheap until you ask 'cheap relative to what.' If 2025 EPS of ~$15 is the base, then 16.5x is fine. But if 2025 is over-earned (it is not -- 2025 is depressed) versus a normalized $20-22 EPS, then 16.5x is fair, not cheap. The DCF in the scorecard says base IV $15.76 against a price of $234 -- a 14.8x price/IV ratio. That is not a valuation; that is a function of the trough cash flow input. The reverse-DCF implied growth is null because the growth assumption needed to bridge price to IV is heroic. In a regime where MA earnings power is rebased 30-40% lower permanently, $234 is a fair price, not a discount, and the multiple should compress to 12x normalized = $240-260, not the $310+ bulls target. The 'GEICO at half price' framing is wrong -- this is more analogous to Buffett's 1981 warning on insurance: 'very large, although obviously varying, underwriting losses will be the norm for the industry, and that the best underwriting years in the future decade may appear substandard against the average year of the past decade' [4].

If I am right, the stock could be worth $130-160 within 24 months.

Lollapalooza Bias Check

Biases active in me as the analyst right now

1. Anchoring (HIGH). The 52-week high of ~$420 and pre-2024 peak of ~$570 are anchoring me to think $234 is 'down a lot' and therefore cheap. But anchoring on the prior peak is exactly the bias Buffett warns against. The right anchor is normalized owner earnings, not prior price. I am partly correcting for this by using book x ROE rather than price history.

2. Recency bias (HIGH). The 2024-25 collapse is so vivid that I am extrapolating either (a) it gets worse forever or (b) it mean-reverts mechanically. Both are recency bias. The reality is that MA cycles play out over 3-5 year arcs and we are in year 2 of a likely 4-year recovery.

3. Confirmation bias (MEDIUM). I came in pre-disposed to like HUM as a 'beaten-down quality' setup. I notice myself reaching for the GEICO analogy [1] and minimizing the regulatory monopsony point. The inversion section is my counter-discipline; I tried to make it genuinely strong rather than a strawman.

4. Authority bias (MEDIUM). The scorecard says composite 73 with 32.6% ROIC. That deterministic Python output is authoritative-feeling and I am tempted to lean on it without questioning whether the inputs reflect a normal-state business. The scorer notes flag 'Maintenance capex uncertain (>50% spread); widen IV range; NOPAT declined; ROIIC not meaningful' -- I should weight these more.

5. Commitment bias (LOW). I have not previously written publicly on HUM, so no commitment to defend. Low risk.

6. Social proof (MEDIUM). The setup is a popular 'fallen angel MCO' trade among value investors -- Pershing Square has been involved historically, and the stock screens cheap on virtually any framework. Crowded value trades can be right but should be sized accordingly.

7. Deprival super-reaction (LOW-MEDIUM). I do feel mild urgency that 'the rebound is happening soon' -- this is a deprival reaction to perceived missed opportunity. Counter: the stock has been at $230-280 for 18 months. There is no rush.

8. Incentive bias (LOW). No personal P&L on this analysis. But broadly: equity research desks are incentive-biased toward 'Buy' calls in beaten-down names because of optionality.

Net effect: my biases are pushing me toward a more bullish call than the evidence warrants. I am compensating by setting a stricter buy price ($200) than my IV math alone would imply ($234 today is already below $283-325 base).

10-Year Outlook

Ten-year outlook test

Same fundamental business model in 2035? YES, with high confidence. Humana will still be a Medicare Advantage carrier. The MA program is so deeply embedded in the federal health architecture that abolition is essentially impossible (51%+ of eligible seniors are enrolled and politically active). The mix between insurance and CenterWell will shift -- CenterWell could be 25-30% of EBIT in 2035 versus ~10% today.

Larger customer base? YES. The 65+ population grows from 58M to 73M+ by 2035. Even at flat MA penetration of 55%, that is ~40M MA enrollees vs 33M today. HUM at ~18% share = 7.2M individual MA members vs 5.2M today. Membership will be larger.

Profit per customer higher? UNCERTAIN. CenterWell vertical integration could lift per-member EBIT by $50-100/year if execution works. But CMS rate compression and v28 phase-in cap the upside on the insurance leg. Net per-member economics likely flat to modestly higher in real terms. This is the central uncertainty.

Moat wider? UNLIKELY. The 32% ROIC era is over. Normalized ROIC will be 15-20% in 2035, which is fine but not a widening moat. CenterWell adds operational depth but is matched by Optum at UNH. Industry moats are narrowing as CMS captures more of the surplus.

Single biggest threat? Political. A bipartisan MA reform bill -- driven by deficit pressure on the IRA reconciliation math -- could compress benchmark rates by 5-10% over 2027-30. This is the only realistic scenario where HUM is structurally impaired. Probability: 25%. Severity if realized: -40% to terminal value.

Confidence assessment. The business model is durable, the customer base will grow, the moat will narrow but not disappear, and the political tail risk is real but not modal. The 32%-ROIC-forever extrapolation is wrong; the permanent-impairment narrative is also wrong. The truth is in the middle: a 15-18% normalized ROIC franchise growing low-double-digit revenue. That is good enough at $234.

CONFIDENCE: medium